α-Helical cell-penetrating peptide-mediated nasal delivery of resveratrol for inhibition of epithelial-to-mesenchymal transition

Kim, Yumin; Hwang, Soonho; Khalmuratova, Roza; Kang, Seok Jin; Lee, Mingyu; Song, Youngjun; Park, Jong-Wan; Yu, Jaehoon; Shin, Hyun Woo; Lu, Yan

doi:10.1016/j.jconrel.2019.11.034

Cited by 38 publications

(21 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In that study, RUNX2-immunoreactive osteoblasts were significantly increased and positively correlated with bone thickness and IL-13 expression in experimental mice. Furthermore, the administration of resveratrol (known to be a SIRT1 activator) reduced mucosal inflammation [78,79] and new bone formation, suggesting the applicability of this murine model for investigating the efficiency of drugs targeting CRS patients with neo-osteogenesis. In a recent study, Kong et al [25] showed that anti-RANKL treatment inhibited mucosal inflammation and related osteitis in a murine model of CRS.…”

Section: Applications Of Animal Models For Elucidating Molecular Mechmentioning

confidence: 97%

Crosstalk Between Mucosal Inflammation and Bone Metabolism in Chronic Rhinosinusitis

Khalmuratova

Shin

2021

Clin Exp Otorhinolaryngol

Self Cite

View full text Add to dashboard Cite

Chronic rhinosinusitis (CRS) is a multifactorial and highly heterogeneous upper airway disease that affects approximately 12% of the general population. There is increasing evidence supporting the impact of osteitis on the pathophysiology of CRS. Osteitis is frequently observed in patients with CRS, and is associated with severe sinonasal inflammation and recalcitrant cases. The overlying inflammatory sinonasal mucosa plays a critical role in the initiation of osteitis; however, the underlying molecular mechanisms and functional significance remain unclear. Increasingly many studies have suggested that immune cells play a crucial role in the bone remodeling process in CRS. The purpose of this review is to summarize the current state of knowledge regarding the specific role of sinonasal inflammation in bone remodeling in CRS patients.

show abstract

Section: Applications Of Animal Models For Elucidating Molecular Mechmentioning

confidence: 97%

Crosstalk Between Mucosal Inflammation and Bone Metabolism in Chronic Rhinosinusitis

Khalmuratova

Shin

2021

Clin Exp Otorhinolaryngol

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is also suggested that the dual drug delivery system combining the advantages of CPPs and nanoparticles can improve the performance, accuracy, half-life, stability, and drug loading capacity of drug delivery systems [168]. Kim et al [169] combined resveratrol (RSV) with amphiphilic CPP (LK) rich in α-Heli leucine (L) and lysine (k) and delivered it to nasal epithelial cells via the nose to inhibit hypoxia-inducible factor-1 α induced epithelial-mesenchymal transition (EMT). In the eosinophilic CRS with NPs mouse model, rsv-lk conjugate can penetrate the nasal epithelium and effectively inhibit EMT, NP formation, epithelial destruction, and related inflammation.…”

Section: Cell-penetrating Peptides (Cpps)mentioning

confidence: 99%

Current Perspective on Nasal Delivery Systems for Chronic Rhinosinusitis

2021

View full text Add to dashboard Cite

Chronic rhinosinusitis is an upper respiratory disease during which topical drug treatment via the nasal cavity is the most actively utilized therapeutic strategy. In addition to steroids, antibiotics, and antifungal agents, which are widely used in clinical practice, research on novel topical agents to improve the bacterial biofilm or mucociliary clearance remains ongoing. Moreover, owing to the complex structure of the nasal cavity, the effects of nasal drug delivery vary depending on factors related to delivery fluid dynamics, including device, volume, and compounds. In this article, we review methods and compounds that have been applied to chronic rhinosinusitis management and introduce recent advances and future perspectives in nasal drug delivery for upper respiratory diseases.

show abstract

“…Kim et al have previously designed an amphiphilic α-helical leucine-and lysine-rich CPP that may have specific advantage in overcoming the mucoepithelial barrier, an important characteristic in the context of local delivery and respiratory system. The authors used intranasal delivery of resveratrol-CPP conjugate and demonstrated drug transport into the nasal epithelium and functional effects related to treatment of chronic rhinosinusitis in a mouse model [43].…”

Section: Lung-targeting Ddsmentioning

confidence: 99%

Status update in the use of cell-penetrating peptides for the delivery of macromolecular therapeutics

Kurrikoff

Vunk

Langel

2020

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction: In this review, recent developments and applications with cell-penetrating peptides (CPP) are discussed. CPPs are widely used tools for the delivery of various macromolecular therapeutics, such as proteins and nucleic acids. Areas covered: The current review focuses on recent important advances and reports that demonstrate high clinical and translational potential. Most important clinical developments have occurred with the CPP-drug conjugate approaches that target various protein-protein interactions, and these have been highlighted subsequently. Most of the applications are targeting cancer, but recently, noteworthy advances have taken place in the field of antisense oligonucleotides and muscular dystrophies, lung targeting, and trans-BBB targeting. Expert opinion: Successful applications and clinical development with the drug conjugate approaches are discussed. On the other hand, the reasons of why the nanoparticle approaches are not as far in development are analyzed.

show abstract

α-Helical cell-penetrating peptide-mediated nasal delivery of resveratrol for inhibition of epithelial-to-mesenchymal transition

Cited by 38 publications

References 52 publications

Crosstalk Between Mucosal Inflammation and Bone Metabolism in Chronic Rhinosinusitis

Crosstalk Between Mucosal Inflammation and Bone Metabolism in Chronic Rhinosinusitis

Current Perspective on Nasal Delivery Systems for Chronic Rhinosinusitis

Status update in the use of cell-penetrating peptides for the delivery of macromolecular therapeutics

Contact Info

Product

Resources

About